WO2001085992A3 - Assay for cell cycle modulators - Google Patents

Assay for cell cycle modulators Download PDF

Info

Publication number
WO2001085992A3
WO2001085992A3 PCT/GB2001/002099 GB0102099W WO0185992A3 WO 2001085992 A3 WO2001085992 A3 WO 2001085992A3 GB 0102099 W GB0102099 W GB 0102099W WO 0185992 A3 WO0185992 A3 WO 0185992A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclin
assay
cell
modulator compound
apc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/002099
Other languages
French (fr)
Other versions
WO2001085992A2 (en
Inventor
Rene Bernards
Reuven Agami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
VERENIGING HET NEDERLANDS KANKER INSTITUUT
Original Assignee
Prolifix Ltd
VERENIGING HET NEDERLANDS KANKER INSTITUUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0011557A external-priority patent/GB0011557D0/en
Priority claimed from GB0016783A external-priority patent/GB0016783D0/en
Application filed by Prolifix Ltd, VERENIGING HET NEDERLANDS KANKER INSTITUUT filed Critical Prolifix Ltd
Priority to AU54980/01A priority Critical patent/AU5498001A/en
Priority to EP01928116A priority patent/EP1282815A2/en
Priority to US10/275,914 priority patent/US20050181360A1/en
Priority to CA002409717A priority patent/CA2409717A1/en
Publication of WO2001085992A2 publication Critical patent/WO2001085992A2/en
Publication of WO2001085992A3 publication Critical patent/WO2001085992A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the finding that cyclin D1 is targeted for destruction in cells which have been exposed to ionising radiation (IR). This finding gives rise to an assay for modulators of cell cycle control, which assay comprises: (a) providing a cell in culture together with apotential modulator compound, said cell expressing a cyclin D1 which undergoes degradation in response to DNAdamage; (b) exposing said cell to a DNA damaging agent; and (c) determining the extent to which the presence of the potential modulator compound inhibits the degradation of said cyclin D1.This finding further gives rise to an assay for modulators of cell cycle control, which assay comprises: (a) providing a cyclin D1, the APC or a componentthereof which interacts with cyclin D1, together with apotential modulator compound; and (b) determining the extent to which the presence of thepotential modulator compound inhibits the interaction ofsaid cyclin D1 and APC or component thereof. In particular where the component of the APC is a protein cdc20.
PCT/GB2001/002099 2000-05-12 2001-05-14 Assay for cell cycle modulators Ceased WO2001085992A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU54980/01A AU5498001A (en) 2000-05-12 2001-05-14 Assay for cell cycle modulators based on the modulation of cyclin d1 degradationin response to ionising radiation
EP01928116A EP1282815A2 (en) 2000-05-12 2001-05-14 Assay for cell cycle modulators
US10/275,914 US20050181360A1 (en) 2000-05-12 2001-05-14 Assay for cell cycle modulators based on the modulation of cyclin d1 degradation in response to ionising radiation
CA002409717A CA2409717A1 (en) 2000-05-12 2001-05-14 Assay for cell cycle modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0011557.6 2000-05-12
GB0011557A GB0011557D0 (en) 2000-05-12 2000-05-12 Assay for cell cycle modulators
GB0016783.3 2000-07-07
GB0016783A GB0016783D0 (en) 2000-07-07 2000-07-07 Assay for cell cycle modulators

Publications (2)

Publication Number Publication Date
WO2001085992A2 WO2001085992A2 (en) 2001-11-15
WO2001085992A3 true WO2001085992A3 (en) 2002-05-23

Family

ID=26244259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002099 Ceased WO2001085992A2 (en) 2000-05-12 2001-05-14 Assay for cell cycle modulators

Country Status (5)

Country Link
US (1) US20050181360A1 (en)
EP (1) EP1282815A2 (en)
AU (1) AU5498001A (en)
CA (1) CA2409717A1 (en)
WO (1) WO2001085992A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469082A1 (en) * 2003-04-16 2004-10-20 Boehringer Ingelheim International GmbH Method of identifying compounds that specifically inhibit the anaphase promoting complex
US8835124B2 (en) 2011-11-04 2014-09-16 The Nemours Foundation Method for treating cancer with agents that bind phosphorylated CDC27

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018974A2 (en) * 1994-01-04 1995-07-13 Mitotix, Inc. Ubiquitin conjugating enzymes
WO1998007852A1 (en) * 1996-08-23 1998-02-26 Vereniging Het Nederlands Kanker Instituut E2f ubiquitination domain, and assays for inhibitors of e2f ubiquitination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2334577A (en) * 1998-02-18 1999-08-25 Univ Liverpool Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein
WO2000027420A1 (en) * 1998-11-06 2000-05-18 The Wistar Institute Of Anatomy And Biology Compositions and methods for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018974A2 (en) * 1994-01-04 1995-07-13 Mitotix, Inc. Ubiquitin conjugating enzymes
WO1998007852A1 (en) * 1996-08-23 1998-02-26 Vereniging Het Nederlands Kanker Instituut E2f ubiquitination domain, and assays for inhibitors of e2f ubiquitination

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BASTIANS HOLGER ET AL: "Cell cycle-regulated proteolysis of mitotic target proteins.", MOLECULAR BIOLOGY OF THE CELL, vol. 10, no. 11, November 1999 (1999-11-01), pages 3927 - 3941, XP002181706, ISSN: 1059-1524 *
ELLEDGE S J ET AL: "The role of protein stability in the cell cycle and cancer", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1377, no. 2, 17 April 1998 (1998-04-17), pages M61 - M70, XP004281818, ISSN: 0304-419X *
HASHEMOLHOSSEINI S ET AL: "RAPAMYCIN INHIBITION OF THE G1 TO S TRANSITION IS MEDIATED BY EFFECTS ON CYCLIN D1 MRNA AND PROTEIN STABILITY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 23, 5 June 1998 (1998-06-05), pages 14424 - 14429, XP000971339, ISSN: 0021-9258 *
HIYAMA HIROFUMI ET AL: "Role for cyclin D1 in UVC-induced and p53-mediated apoptosis.", CELL DEATH AND DIFFERENTIATION, vol. 6, no. 6, June 1999 (1999-06-01), pages 565 - 569, XP001036637, ISSN: 1350-9047 *
See also references of EP1282815A2 *
SHERR C J ET AL: "INHIBITORS OF MAMMALIAN G1 CYCLIN-DEPENDENT KINASES", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 9, no. 10, 15 May 1995 (1995-05-15), pages 1149 - 1163, XP000572027, ISSN: 0890-9369 *
YAMANO HIROYUKI ET AL: "The role of proteolysis in cell cycle progression in Schizosaccharomyces pombe.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 15, no. 19, 1996, pages 5268 - 5279, XP002181707, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
EP1282815A2 (en) 2003-02-12
CA2409717A1 (en) 2001-11-15
US20050181360A1 (en) 2005-08-18
AU5498001A (en) 2001-11-20
WO2001085992A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
EA200400186A1 (en) REGULATION OF EXTRESSION OF HINOLYAT PHOSPHYRBOSYL TRANSFERASE
TR199902426T2 (en) Control of plant pests.
TR199800046A2 (en) Formation of nucleic acid to create active substances.
ES2184340T3 (en) COMBINATIONS OF INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME AND INHIBITORS OF THE MATRIX METALOPROTEINASE ENZYME.
WO2004081185A3 (en) Methods to enhance the activity of lignocellulose-degrading enzymes
EP1063286A4 (en) Substrates for immobilizing and amplifying dna, dna-immobilized chips having dna immobilized on the substrates, and method for amplifying dna
ES2113105T3 (en) REAGENTS FOR USE IN BIOLUMINESCENCE.
WO2004061418A3 (en) Assay cartridges and methods of using the same
DK1280898T3 (en) Modified ES cells and ES cell specific gene
AU2003241311A1 (en) Simple catalytic dna biosensors for ions based on color changes
DE69839133D1 (en) Isolation of nucleic acids
ES2187622T3 (en) REAGENTS AND TEST DEVICES.
WO2001036641A3 (en) DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
WO2005022113A3 (en) Ion channel assay methods
BR0316324A (en) Interferon-alpha polypeptides and conjugates
DK1124945T3 (en) matrix Granules
EA200400021A1 (en) METHOD OF STABILIZATION OF REAGENT FOR AMPLIFICATION OR DETECTION OF NUCLEIC ACID AND STORAGE METHOD
ES2144507T3 (en) BACILLUS PESTICIDE ACTIVITY POTENTIAL.
DE60103428D1 (en) IDENTIFICATION OF CELLS DURING KINETIC TEST SERIES
WO2001085992A3 (en) Assay for cell cycle modulators
WO2003008635A8 (en) η-SECRETASE IN VITRO SCREENING ASSAY
WO1999058947A3 (en) Modulation of molecular interaction sites on rna and other biomolecules
AU5871899A (en) Biosensor
NO960826L (en) Use of enzymes from krill in substances
HK1040420A1 (en) Metabolic selection methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2409717

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001928116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275914

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001928116

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928116

Country of ref document: EP